

Second primary malignancies in patients with non-melanoma skin cancer: results from a cancer registry–based study in Emilia Romagna, north-east Italy

Alessandro Borghi¹, Monica Corazza¹, Giorgio Chiaranda², Maria Michiara³, Lucia Mangone⁴, Bianca Caruso⁵, Fabio Falcini⁶, Iva Maestri⁷, Stefano Ferretti⁸

¹Department of Medical Sciences, Section of Dermatology and Infectious Diseases, University of Ferrara, Ferrara, Italy

²Piacenza Cancer Registry, Local Health Unit, Piacenza, Italy

³Parma Cancer Registry, University Hospital of Parma, Parma, Italy

⁴Reggio Emilia Cancer Registry, Epidemiology Unit, Local Health Unit-IRCCS Reggio Emilia, Reggio Emilia, Italy

⁵Modena Cancer Registry, Public Health Department, Local Health Unit Modena, Modena, Italy

⁶Romagna Cancer Registry, Romagna Cancer Institute, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST, IRCCS, Meldola, Forlì, Italy

⁷Department of Experimental and Diagnostic Medicine, University of Ferrara, Ferrara, Italy.

⁸Department of Morphology, Surgery and Experimental Medicine, University of Ferrara; Local Health Authority Ferrara, Ferrara, Italy

Word counts of the abstract: 243

Word counts of the manuscript: 3153

Word count of the highlights: 61

Short title: Second primary malignancies in non-melanoma skin cancer patients

Declarations of interest: none

Corresponding Author:

Alessandro Borghi

Department of Medical Sciences, Section of Dermatology and Infectious Diseases

University of Ferrara, Ferrara, Italy

Via L. Ariosto 35, 44121 Ferrara, Italy

Tel: 0039 0532/239684 Fax: 0039 0532/206791

E-mail: alessandro.borghi@unife.it

Abstract

Background: previous research on the risk of subsequent, primary non-cutaneous malignancies among patients with non-melanoma skin cancers (NMSCs) led to conflicting results. We aimed to investigate a possible link between NMSC and second primary malignancies by using the population-based data available in cancer registries.

Methods: this observational study retrospectively assessed the risk of occurrence of both synchronous and methachronous second primary tumours in a cohort of cancer patients whose first diagnosis was NMSC. The cohort came from the network of general cancer registries of the Emilia-Romagna Region, northeast Italy, in the period between 1978 and 2012, and was compared with the general population living in the same area. Two main indexes were used: i) Standardized Incidence Ratio (SIR), calculated as the ratio between the observed and the expected number of second cancers and ii) Excess Absolute Risk (EAR), expressing the absolute excess or deficit of second cancer incidence.

Results: in the period analysed (1978-2012, 72,503,157 person/years, PYs), 89,912 primary NMSC were found in 76,414 patients. Among them, 14,195 developed a second primary cancer in the subsequent 501,763 follow-up PYs. NMSC patients showed an overall SIR of 1.22 (CI 95% 1.20-1.24) and an EAR of 5.11 cases/1,000 PYs (CI 95% 4.48-5.74).

Conclusions: the study results showed that NMSC patients had an increase in relative risk and, at least for some tumours, in absolute risk of developing a second cancer when compared with the general population. Genetic, environmental and personal risk factors may influence this finding.

Key Words: non-melanoma skin cancers, subsequent primary malignancies, cancer survivors, cancer registry, Standardized Incidence Ratio, Excess Absolute Risk

1. Introduction

Cancer survivors have increased over the past few decades, due to the increase in early diagnosis and the improvement in treatment and supportive care [1-3]. One of the most serious late effects among cancer survivors is the development of additional malignancies, either recurrences or new primary cancers. They arise as a result of numerous factors, such as genetic predisposition, aging, lifestyle choices, environmental exposures, mutagenic effects of previous cancer treatments, and their interactions [4]. The reported incidence of new malignancies in cancer survivors varies considerably, but they are estimated to account for 16% of all cancers [5].

Non-melanoma skin cancers (NMSCs), which essentially include basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), are by far the most common malignancies in white populations [6]. Although NMSCs are usually curable, they represent a major public health problem due to their high prevalence and expense of treatment [7]. Subjects with NMSCs are known to be at increased risk of developing subsequent NMSCs, as well as malignant melanoma, probably due to the shared phenotypic and environmental risk factor, mainly ultraviolet (UV) radiation [8-10]. Biased ascertainment of new skin primaries as a result of increased dermatological surveillance should be taken into account, too. Accumulating evidence seems to support the fact that a personal history of NMSC also exposes to an increased risk for second primary cancers other than just skin tumours [11], although an inverse association has been found as well [12].

A recent systematic review, which aimed to address this issue by assessing the available evidence on this topic, mostly based on national cancer registry data, revealed strong evidence that NMSC is associated with an approximately 10% increased risk of subsequent primary cancer other than NMSC [13].

The purpose of the present study was to investigate a possible link between NMSC and subsequent primary malignancies by using the population-based data available in cancer registries.

2. Materials and methods

2.1. Study setting

This observational study analysed a retrospective cohort of cancer patients whose first diagnosis was non-melanoma skin cancer (NMSC). The cohort came from the network of general cancer registries of the Emilia-Romagna Region in northeast Italy, (with about 3,500,000 residents in 2010) belonging to the Italian Cancer Registry Association (AIRTUM). All data were validated by the International Agency for Research on Cancer (IARC) [14] and covered an overall period from 1978 to 2012, but were different for each province (due to the longer casuistry of the Parma province, with its 426,000 inhabitants, from 1978 to 2012 with respect to the period 2006-2011 for the Piacenza province, with 290,000 inhabitants).

NMSC included in the study were SCC, BCC, appendage carcinomas and mixed tumours (carcino-sarcomas), according to the ICD-O 3 classification [15] topography (codes from C44.0 to C44.9) and morphology (M-8000 – M-8575; M-8940; M-8980, with behaviour 5th code /3). **A brief analysis considering separately patients with primary SCC (ICD-O 3 M-8050-8084) and those with primary BCC (ICD-O 3 M-8090-8110) was conducted as well.** In accordance with the IARC and European Network of Cancer registries (ENCR) rules, for each patient, a tumour to be considered and included as a second primary cancer should not be an extension, a recurrence or a metastasis from a previous tumour [16,17]. SCC and BCC were considered “different” tumours (multiple) when present in a single patient. A check by IARCCrgTools [18] program was performed in order to avoid registration errors or biases for first and second primaries.

The study assessed the risk of occurrence of second primary tumours in NMSC patients, both synchronous (i.e. within 2 months from the diagnosis of primary NMSC) and methachronous (diagnosed 2 months or later after the first tumour) [19], compared with the risk of the general population living in the same area.

2.2 Analysis

Person-years at risk (PYs) were defined as the period from first NMSC to the second cancer incidence or last known vital status/death or last follow-up (2013 or 2014 depending on each registry). Patients

without follow-up after the first primary NMSC, for example in the case of Death Certification Only or autopsy diagnosis, were excluded from this analysis.

Two main indexes were used to check the hypothesis of a higher cancer incidence risk of NMSC patients in respect to the general population: i) Standardized Incidence Ratio (SIR), calculated as the ratio between the observed and the expected number of second cancers (the latter on the basis of their incidence in the general reference population), and ii) Excess Absolute Risk (EAR), expressing the absolute excess or deficit of second cancer incidence (difference between the rate of the observed number of second cancers and the rate of expected ones).

2.3. Statistics

Analyses were performed by MP-SIR session of SEERStat Software [19]: SIR and EAR were expressed by sex, latency of the second tumour, attained age and period at the second diagnosis. Confidence Intervals (CIs) at 95% and 99.9% were calculated according to Poisson distribution. Statistical p was considered significant for values <0.05 and <0.001.

3. Results

3.1. Overall second cancer occurrence risk

In the period studied (1978-2012, 72,503,157 person/years), 89,912 primary NMSC were found in 76,414 patients. Among them, 14,195 developed a second primary cancer in the subsequent 501,763 follow-up PYs. Therefore, these patients showed an overall SIR of 1.22 (CI 95% 1.20-1.24) and an EAR of 5.11 cases/1,000 PYs (CI 95% 4.48-5.74). Second cancers after at least a 2-months interval from the first were 13,525 (in 489,207 p/y), with a SIR of 1.19 (CI 95% 1.17-1.21) and an EAR of 4.42 cancers/1,000 PY (CI 95% 4.48-5.74).

3.2. Second cancer occurrence by gender

In male subjects, relevant second methachronous cancer risk excesses were found in head and neck cancer (SIR=1.36, higher after a 12 month latency), salivary glands (SIR=3.77, higher in the first 5 years of latency), liver (SIR=1.22), lung (SIR=1.24), skin melanomas and other skin cancers

(SIR=2.38 and 1.30, respectively, constant in all ≥ 2 months follow-up period), soft tissues (SIR=1.63), prostate (SIR=1.17, constant from 2 to over 120 months of follow up), non-Hodgkin lymphomas (SIR=1.45, constant in the first ten years after primary NMSC), leukemias (SIR=1.22), all-site tumors (SIR=1.20) and all sites excluding NMSC and melanomas (SIR=1.17).

Absolute excess (EAR) of second synchronous and metachronous tumours was, respectively, 66.10 and 57.97/10,000 PYs. Higher risks were observed in other skin carcinomas (total EAR $\cong 27$; metachronous EAR $\cong 17$), lung (both EAR $\cong 10$), prostate (both EAR $\cong 8$), melanomas (both EAR $\cong 5$), non-Hodgkin lymphomas (both EAR $\cong 3$), head and neck (both EAR $\cong 3$) and liver (both EAR $\cong 2$). Only soft tissue metachronous tumours showed a significant reduction of EAR ($\cong 0.6$). Detailed SIRs by follow-up period and EARs for males are reported in Table 1.

In female subjects the excesses of overall risks of multiple (metachronous) tumours mainly concerned salivary glands (SIR=3.62), oesophagus (SIR=1.89), stomach (SIR=1.18), colon (SIR=1.16), pancreas (SIR=1.23), lung (SIR=1.23), cutaneous melanoma (SIR=2.35, present in all follow-up periods and higher in the first year), soft tissues (SIR=1.61), breast (SIR=1.19, constant after the first year), kidney (SIR=1.27), urinary tract (renal pelvis and ureter SIR=1.94), Hodgkin and non-Hodgkin lymphomas (SIR=2.02 and 1.31 respectively), leukemias (SIR=1.36), all-site tumours (SIR=1.17) and all sites excluding NMSC and melanomas (SIR=1.20).

In females, EAR x 10,000 PYs showed excesses in breast cancer (EAR $\cong 5$ both synchronous and metachronous), skin melanoma (EAR $\cong 3$), other skin carcinomas (overall EAR $\cong 6$, concentrated in the early follow up), colon (EAR $\cong 2$), lung and non-Hodgkin lymphomas (EAR $\cong 2$). Overall EAR, including both synchronous and metachronous cancers, was $\cong 33$, whereas it was $\cong 28$ for metachronous tumours only. Detailed data for SIR and EAR for several follow-up periods are shown in Table 2. A brief overview of SIRs in males and females by latency of second tumour is also shown in Figure 1.

3.3. Second cancer occurrence by study period

Three different periods of the study (1978-; 1990-; 2000-) with progressively longer follow-up for each patient (average 2.5; 3.9; 6.1 years, respectively) were taken into account (Table 3). Males showed an increased risk of second methachronous (latency ≥ 2 months) salivary glands, lung, other skin and all-sites tumours over the entire observational period. Head and neck, skin melanomas, and non-Hodgkin lymphomas showed higher SIR only from the nineties onwards, whereas liver, soft tissues and prostate only over the last period (2000-). In females, the excesses of risk regarded mainly the salivary glands, melanomas and the breast, from the middle of the period studied, (from 1990 onwards), with the extension of patient follow-up.

3.4. Second cancer occurrence by the patients' age

Analysing the age of second tumour occurrence (Table 4), cutaneous melanomas, other skin tumours and non-Hodgkin lymphomas in males, skin melanomas and the breast in females, showed the highest risks at all ages, with a decreasing gradient as life progresses. All tumours showed the same excess of risk and the same gradient.

3.5 Second cancer occurrence by sex in patients with SCC and BCC

A brief overview of risks of subsequent cancers in patients with SCC and BCC, considered separately, is shown in Table 5. Overall, SCC tended to be associated with a higher risk of multiple cancers, compared to BCC. BCCs were associated with a higher risk, both in males and females, especially for skin melanomas.

4. Discussion

Previous studies examining a possible relationship between NMSCs and subsequent increased risk of primary non-cutaneous malignancies have yielded conflicting findings [21-30].

In order to further assess this issue, the present study took into consideration a large number of NMSC patients over a notable amount of time. The source of data from population cancer registries guaranteed against selection biases, which can affect studies based on different sources. Emilia Romagna cancer registries record all cases of histologically confirmed NMSC, excised from both

inpatients and outpatients. The choice to include only second tumours was made to avoid the confounding effect of other cancers, and relative therapies, on the risk of multiple primaries. The assessment of both second synchronous and metachronous tumours, which occurred at different time intervals from the first NMSC diagnosis, was aimed at differentiating the potential effect of "screening" of the patient in relation to the first diagnosis, from the effective incidence of a second tumour.

In this study, we considered the relative (SIR) excess of risk, calculated also in previous studies, but also the absolute (EAR) excess of risk. In relatively rare events, such as those addressed, a high relative risk does not always mean an effective excess of observed cases. Thus, we chose to investigate both SIR and EAR for a better definition of the real burden of this risk for health care.

The main finding of the present study was that NMSC patients were shown to have a higher risk (average +22%) of developing a second primary malignant cancer in comparison with the general population, both in males (+23%) and females (+20%). It is worthy of note that an increased occurrence of subsequent primary malignant cancers in NMSC patients, compared with those who had no such history, was found also excluding skin cancers. SIR values were quite similar when considering the second tumours as a whole and excluding the second skin tumours. This suggests that this relative excess of risk was independent from belonging to the same anatomical district. For some tumours, such as skin cancers and melanoma, female breast, male upper aerodigestive tract, lung, prostate, liver, and non-Hodgkin lymphomas, this higher relative risk also resulted in a relevant, effective increase in cancer occurrence when compared to those expected. Some risk differences were found according to gender (Tables 1 and 2), period of observation (Table 3) and the patients' age (Table 4). Considering SCC and BCC separately, we found some differences too (Table 5). This is not surprising as these two tumours, although both belonging to keratinocytes, are very different from many points of view, such as etiology, pathogenesis, behaviour, growth, and metastatic capability [31,32]. In particular, differences in molecular and genetic factors involved in SCC and BCC carcinogenesis may account for their different associations with subsequent primary tumours.

Although a tendency to a higher risk of subsequent cancers was found for SCC compared to BCC, the latter was highly significantly associated with the risk of subsequent skin melanoma. Aberrant activation of Hedgehog (HH) signalling, which is a key regulator of tissue development, is involved in several cancer types, mainly, at skin level, BCC [33]. Recent studies showed that HH signalling is dysregulated also in cutaneous melanoma [34,35], suggesting a shared pathway between BCC and melanoma which could, at least in part, explain our finding.

Overall, the recognized increase in incidence of multiple tumours in recent years can be explained by several factors, like the increase in survival, growing diagnostic sensitivity, particularly for indolent neoplasms, and increased clinical and instrumental surveillance of patients treated for cancer. In our population, the highest SIR observed in the first month after the diagnosis of NMSC (Figure 1) may be partly due to the medical consultation related to skin cancer. This may have favoured the finding of further concomitant cancers. However, specific genetic, environmental and personal risk factors concur to this trend as well [36,37]. In keeping with this, the risk of subsequent cancer remained higher in patients with NMSC, compared to the general population, even years after the diagnosis of the first tumour (Figure 1). We give the results of our focus on the most relevant associations between NMSCs and second primary tumours below, and try to identify possible explanations for these associations.

NMSC patients, both squamous and basal cell type, had higher relative risk of incidence of salivary gland tumours, as documented by other studies [23,38], although the absolute risk estimated in this study is low. From a biological point of view, the basis of this association could be due to risk factors in common between the two tumours, namely tobacco smoking, UV exposure, and immunodeficiency, all of which potentially mutate p53 alleles [39].

Women with previous NMSC showed a moderate, but significantly higher risk of developing gastric cancer in respect to the general population, as shown by other studies [28,38]. In this association, tobacco smoking may represent a shared risk factor [40], together with the inflammatory response to helicobacter pylori infection that plays a role in other skin diseases [41], like other common pathways

linked to interleukin 10 [42,43]. Both NMSC and gastric cancer recognize the aberrant Hedgehog signalling activation [44].

The Danish cancer registry found a higher SIR of respiratory tract cancers among NMSC patients similar to that shown in the present study [26] as well as in others [11,13,28,37,38]. Tobacco is obviously a common risk factor [45]. Among the biological bases of this association, the alterations of p53 and p16 probably represent a shared pathway [46]. Furthermore, a shared mutation of CSMD1 was found in 36% of lung tumours, 29% of skin SCC and in 17% of BCC [47].

The association between NMCC and cutaneous melanoma had been widely reported [11,13,25,26,28,38]. The genotoxic effect of UV radiation is the greatest common risk factor, although SCC onset has been notoriously associated with chronic exposition to UV, while an intermittent UV exposure is mainly linked to skin melanoma and BCC occurrence [48]. **This latter point may further support the stronger association observed in our study between BCC and subsequent melanoma, together with the aforesaid common dysregulation of HH signalling.** Apart from the mutagenic effect of UV exposure, mainly on CDKN2A [49], defective DNA repair, chronic inflammation and immunosuppression also play a shared role both in melanoma and NMSC incidence.

The association between breast carcinoma and NMSC had emerged from previous studies [11,23,26,28,38]. Possible common biological pathways are CDKN2A and p53 genetic and epigenetic mutations [48,50].

An increased risk of prostate cancer after NMSC had already been observed in other studies. In this association as well tobacco smoke plays a relevant role. Heavy smokers are at high risk for prostate cancer and they frequently develop a high grade carcinoma [51]. UV exposure could also be a common risk factor. Indeed, the immunosuppression induced by UV radiation had already been associated with prostate cancer onset as well [52]. Finally, aberrant Hedgehog signalling activation had been referred to basal cell and prostate carcinoma incidence [53,54].

NMSC patients also have a higher risk of onset of NHL, as seen in several other population studies [13,26,38]. Immunosuppression, both iatrogenic and induced by UV exposure, or infections (HIV), may represent the main shared risk factor [55].

Several studies have shown the relationships between NMSC and leukemia incidence [13,26-28,38]. Apart from immunosuppression [56], also the exposure to toxic agents like benzene, present in tobacco smoke as well, could be the *trait d'union* between the onset of NMSC and of acute myeloid leukemia (most frequent in adults). Other studies have found that in smokers the risk of acute myeloid leukemia increases up to 40% [57] and that of NMSC to 52% [58]. Some gene polymorphisms had been linked to both NMSC and leukemia incidence risk; in particular some polymorphisms of IRF4, belonging to Interferon Regulatory Factor (IRF), could intervene both in the development and the progression of skin and haematological tumours, playing an essential role in their pathogenesis [59]. Therefore, in view of what is currently conceivable, both multiple environmental agents and intrinsic risk factors, such as genetic and epigenetic changes favouring cellular transformation in different tissues, may be responsible for the risk of multiple tumours in NMSC patients.

While commenting on the results of the study, it is necessary to underline that some factors potentially predisposing to an increased chance of second tumour diagnosis for many types of cancer have less relevance for skin tumours, especially NMSCs. NMSC patients are subjected neither to aggressive therapies nor to in-depth screening. For these reasons, the association between NMSC and the risk of developing other cancers is likely to represent a true etiologic association. On the other hand, the indolence of NMSCs and the prolonged survival of NMSC patients allow them to be followed up for a long time. Thus, NMSCs can be a model for studying the development of multiple tumours, specifically the pathomechanisms underlying this phenomenon.

The present study showed an increase not only in the relative risk but, at least for some tumours, also in the absolute risk among NMSC patients of developing a second cancer. However, a general screening and a specifically planned follow up for NMSC patients remain difficult to justify, considering their enormous number, especially in Western countries.

The present study has some limitations. Being registry-based, it lacks information about hypothesised risk factors, including UV or other environmental exposures, lifestyle choices, socioeconomic status, treatments. NMSCs either not histologically diagnosed or misdiagnosed, for example as pre-malignant lesions, are missed. Our study included a predominantly white population and cannot be applied to other ethnic groups.

5. Conclusions

In conclusion, based on our study findings, NMSC could be considered a kind of “sentinel event” indicating a population with a long-lasting, increased risk regarding several multiple primaries, thus confirming previous findings. Although there are no requirements supporting an active screening for these patients, NMSC highlights the presence of shared, environmental risks to be removed and active biological pathways which should be further investigated.

References

1. Valdivieso M, Kujawa AM, Jones T, Baker LH. Cancer survivors in the United States: a review of the literature and a call to action. *Int J Med Sci.* 2012;9:163-73. DOI: 10.7150/ijms.3827
2. Ries LAG., Harkins, D, Krapcho M, Mariotto A. Miller BA, Feuer EJ et al. SEER cancer statistics review, 1975–2003. Bethesda, MD: National Cancer Institute; 2006.
3. Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB, et al. Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. *J Natl Cancer Inst.* 2006;98:15-25. DOI: 10.1093/jnci/djj001
4. Hudson, MM. A model for care across the cancer continuum. *Cancer.* 2005;104(Suppl.):2638–42. DOI: 10.1002/cncr.21250
5. Travis LB. The epidemiology of second primary cancers. *Cancer Epidemiol Biomarkers Prev.* 2006;15:2020-6. DOI: 10.1158/1055-9965.EPI-06-0414

6. Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. *Arch Dermatol.* 2010;146:283-7. DOI: 10.1001/archdermatol.2010.19
7. Chen JG, Fleischer AB Jr, Smith ED, Kancler C, Goldman ND, Williford PM et al. Cost of nonmelanoma skin cancer treatment in the United States. *Dermatol Surg.* 2001;27:1035-8.
8. Rosenberg CA, Khandekar J, Greenland P, Rodabough RJ, McTiernan A. Cutaneous melanoma in postmenopausal women after nonmelanoma skin carcinoma: the Women's Health Initiative Observational Study. *Cancer.* 2006;106:654-63. DOI: 10.1002/cncr.21627
9. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. *Arch Dermatol.* 2000;136:1524-30.
10. Lovatt TJ, Lear JT, Bastrilles J, Wong C, Griffiths CE, Samarasinghe V et al. Associations between ultraviolet radiation, basal cell carcinoma site and histology, host characteristics, and rate of development of further tumors. *J Am Acad Dermatol.* 2005;52 :468– 73 . DOI: 10.1016/j.jaad.2004.08.060
11. Song F, Qureshi AA, Giovannucci EL, Fuchs CS, Chen WY, Stampfer MJ, et al. Risk of a second primary cancer after non-melanoma skin cancer in white men and women: a prospective cohort study. *PLoS Med.* 2013;10:e1001433. DOI: 10.1371/journal.pmed.1001433
12. Wilkins KL, Woodgate RL. Preventing second cancers in cancer survivors. *Oncol Nurs Forum.* 2008;35:E12-22. Doi: 10.1188/08.ONF.E12-E22.
13. Wheless L, Black J, Alberg AJ. Nonmelanoma skin cancer and the risk of second primary cancers: a systematic review. *Cancer Epidemiol Biomarkers Prev.* 2010;19:1686-95. DOI: 10.1158/1055-9965.EPI-10-0243.
14. World Health Organization. *Cancer Incidence in Five Continents vol I to X.* <http://ci5.iarc.fr/CI5I-X/Pages/references.aspx>

15. World Health Organization, International Classification of Diseases for Oncology – Third edition (Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S eds), Geneva, 2000.
16. Crocetti E, Lecker S, Buiatti E, Storm HH. Problems related to the coding of multiple primary cancers. *Eur J Cancer*. 1996;32:1366-70.
17. Pheby D, Martinez C, Roumagnac M, Schouten L. Recommendations for coding multiple primaries. European Network of Cancer Registries (ENCR); 1995 (revised in 2000 and 2004).
18. Ferlay J. IARCcrgTools version 2.05. Section of Cancer Surveillance, International Agency for Research on Cancer (IARC), Lyon 2005.
19. AIRTUM Working Group. Italian cancer figures – report 2013. Multiple Tumours. *Epidemiol Prev* 2013; 4/5 suppl 1: 11-17.
20. SEER*Stat v. 8.3.4. <https://seer.cancer.gov/seerstat>.
21. Cantwell MM, Murray LJ, Catney D, Donnelly D, Autier P, Boniol M, et al. Second primary cancers in patients with skin cancer: a population-based study in Northern Ireland. *Br J Cancer*. 2009;100:174-7. DOI: 10.1038/sj.bjc.6604842.
22. Chen J, Ruczinski I, Jorgensen TJ, Yenokyan G, Yao Y, Alani R, et al. Nonmelanoma skin cancer and risk for subsequent malignancy. *J Natl Cancer Inst*. 2008;100:1215-22. DOI: 10.1093/jnci/djn260.
23. Levi F, Randimbison L, Te VC, Conconi MM, La Vecchia C. Risk of prostate, breast and colorectal cancer after skin cancer diagnosis. *Int J Cancer*. 2008;123:2899-901. DOI: 10.1002/ijc.23816.
24. Maitra SK, Gallo H, Rowland-Payne C, Robinson D, Møller H. Second primary cancers in patients with squamous cell carcinoma of the skin. *Br J Cancer*. 2005;14;92:570-1. DOI: 10.1038/sj.bjc.6602306

25. Milán T, Pukkala E, Verkasalo PK, Kaprio J, Jansén CT, Koskenvuo M, et al. Subsequent primary cancers after basal-cell carcinoma: A nationwide study in Finland from 1953 to 1995. *Int J Cancer*. 2000;87:283-8.
26. Frisch M, Hjalgrim H, Olsen JH, Melbye M. Risk for subsequent cancer after diagnosis of basal-cell carcinoma. A population-based, epidemiologic study. *Ann Intern Med*. 1996;125:815-21.
27. Nugent Z, Demers AA, Wiseman MC, Mihalcioiu C, Kliwer EV. Risk of second primary cancer and death following a diagnosis of nonmelanoma skin cancer. *Cancer Epidemiol Biomarkers Prev*. 2005;14:2584-2590. DOI:10.1158/1055-9965.EPI-05-0379
28. Rosenberg CA, Greenland P, Khandekar J, Loar A, Ascensao J, Lopez AM. Association of nonmelanoma skin cancer with second malignancy. *Cancer*. 2004;100:130-8. DOI: 10.1002/cncr.11874
29. Efird JT, Friedman GD, Habel L, Tekawa IS, Nelson LM. Risk of subsequent cancer following invasive or in situ squamous cell skin cancer. *Ann Epidemiol*. 2002;12:469-75.
30. Wassberg C, Thörn M, Yuen J, Ringborg U, Hakulinen T. Second primary cancers in patients with squamous cell carcinoma of the skin: a population-based study in Sweden. *Int J Cancer*. 1999;80:511-5.
31. Didona D, Paolino G, Bottoni U, Cantisani C. Non Melanoma Skin Cancer Pathogenesis Overview. *Biomedicines*. 2018;6. pii: E6. DOI: 10.3390/biomedicines6010006.
32. Emmert S, Schön MP, Haenssle HA. Molecular biology of basal and squamous cell carcinomas. *Adv Exp Med Biol*. 2014;810:234-52.
33. Epstein EH. Basal cell carcinomas: attack of the hedgehog. *Nat Rev Cancer* 2008;8:743–54. DOI: 10.1038/nrc2503.
34. Pandolfi S, Montagnani V, Lapucci A, Stecca B. HEDGEHOG/GLI-E2F1 axis modulates iASPP expression and function and regulates melanoma cell growth. *Cell Death Differ*. 2015;22:2006-19. DOI: 10.1038/cdd.2015.56.

35. Santini R, Vinci MC, Pandolfi S, Penachioni JY, Montagnani V, Olivito B, et al. Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells. *Stem Cells*. 2012;30:1808-18. DOI: 10.1002/stem.1160.
36. Nielsen SF, Nordestgaard BG, Bojesen SE. Associations between first and second primary cancers: a population-based-study. *CMAJ*. 2012;10:E57-E69. DOI: 10.1503/cmaj.110167
37. Buiatti E, Crocetti E, Acciai S. Incidence of second primary cancers in three italian population-based cancer Registries. *Eur J Cancer*. 1997;11:1829-34.
38. Ong EL, Goldacre R, Hoang U, Sinclair R, Goldacre M. Subsequent primary malignancies in patients with nonmelanoma skin cancer in England: a national record-linkage study. *Cancer Epidemiol Biomarkers Prev*. 2014;23:490-8. DOI:10.1158/1055-9965.EPI-13-0902
39. Danaee H, Nelson HH, Karagas MR, Schned AR, Ashok TD, Hirao T, et al. Microsatellite instability at tetranucleotide repeats in skin and bladder cancer. *Oncogene*. 2002;21:4894-9. DOI: 10.1038/sj.onc.1205619
40. Praud D, Rota M, Pelucchi C, Bertuccio P, Rosso T, Galeone C, et al. Cigarette smoking and gastric cancer in the Stomach Cancer Pooling (StoP) Project. *Eur J Cancer Prev*. 2018;27:124-33. DOI:10.1097/CEJ.0000000000000290
41. Kutlubay Z, Zara T, Engin B, Serdaroğlu S, Tüzün Y, Yılmaz E, et al. Helicobacter pylori infection and skin disorders. *Hong Kong Med J*. 2014;20:317-24. DOI: 10.12809/hkmj134174
42. Qi M, Liu DM, Pan LL, Lin YX. Interleukin-10 gene -592C>A polymorphism and susceptibility to gastric cancer. *Genet Mol Res*. 2014;13:8954-61. DOI: 10.4238/2014.October.31.10.
43. Alamartine E, Berthoux P, Mariat C, Cambazard F, Berthoux F. Interleukin-10 promoter polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation. *J Invest Dermatol*. 2003;120:99-103. DOI:10.1046/j.1523-1747.2003.12016.x

44. Katoh Y, Katoh M. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. *Curr Mol Med.* 2009;9:873-86.
45. Park SM, Li T, Wu S, Li WQ, Qureshi AA, Stampfer M, et al. Risk of second primary cancer associated with pre-diagnostic smoking, alcohol, and obesity in women with keratinocyte carcinoma. *Cancer Epidemiol.* 2017;47:106-13. DOI: 10.1016/j.canep.2017.02.002.
46. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (eds). WHO classification of Tumors of Lung, Pleura, Thymus and Heart -. 4th edition. IARC, Lyon 2015.
47. Ma C, Quesnelle KM, Sparano A, Rao S, Park MS, Cohen MA, et al. Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. *Cancer Biol Ther.* 2009;8:907-16.
48. Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. *In Vivo.* 2014;28:1005-11.
49. Zhang H, Bermejo JL, Sundquist J, Hemminki K. Modification of second cancer risk after malignant melanoma by parental history of cancer. *Br J Cancer.* 2008;99:536-8. DOI: 10.1038/sj.bjc.6604489
50. Bertheau P, Lehmann-Che J, Varna M, Dumay A, Poirot B, Porcher R, et al. p53 in breast cancer subtypes and new insights into response to chemotherapy. *Breast.* 2013;22:S27-S29. DOI: 10.1016/j.breast.2013.07.005
51. Murphy AB, Akereyeni F, Nyame YA, Guy MC, Martin IK, Hollowell CM, et al. Smoking and prostate cancer in a multi-ethnic cohort. *Prostate.* 2013;73:1518-28. DOI: 10.1002/pros.22699.
52. Nair-Shalliker V, Smith DP, Egger S, Hughes AM, Kaldor JM, Clements M, et al. Sun exposure may increase risk of prostate cancer in the high UV environment of New South Wales, Australia: a case-control study. *Int J Cancer.* 2012;131:E726-E732. DOI: 10.1002/ijc.27400.

53. Gonnissen A, Isebaert S, Haustermans K. Hedgehog signaling in prostate cancer and its therapeutic implication. *Int J Mol Sci.* 2013;14:13979-4007. DOI: 10.3390/ijms140713979
54. Otsuka A, Levesque MP, Dummer R, Kabashima K. Hedgehog signaling in basal cell carcinoma. *J Dermatol Sci.* 2015;78:95-100. DOI: 10.1016/j.jdermsci.2015.02.007
55. Adami J, Frisch M, Yuen J, Glimelius B, Melbye M. Evidence of an association between non-Hodgkin's lymphoma and skin cancer. *BMJ.* 1995;10;310:1491-5.
56. Gale RP, Opelz G. Commentary: does immune suppression increase risk of developing acute myeloid leukemia? *Leukemia.* 2012;26:422-3. DOI: 10.1038/leu.2011.224
57. Fircanis S, Merriam P, Khan N, Castillo JJ. The relation between cigarette smoking and risk of acute myeloid leukemia: an updated meta-analysis of epidemiological studies. *Am J Hematol.* 2014;89:E125-E132. DOI: 10.1002/ajh.23744.
58. Leonardi-Bee J, Ellison T, Bath-Hextall F. Lifestyle factors of smoking, BMI and alcohol on the risk of Non-Melanoma Skin Cancer in adults: a systematic review. *JBIC Libr Syst Rev.* 2012;10:352-98.
59. Wang S, Yan Q, Chen P, Zhao P, Gu A. Association of interferon regulatory factor 4 gene polymorphisms rs12203592 and rs872071 with skin cancer and haematological malignancies susceptibility: a meta-analysis of 19 case-control studies. *BMC Cancer.* 2014;14:410. DOI: 10.1186/1471-2407-14-410

Figure Legend

Figure 1. SIR of second cancers in males and females (ICD-10 C00-C96, all sites)

Table 1. SIR & EAR x 1,000 male skin carcinoma patients by second cancer site and follow-up period

Second cancer site	SIR ¹							EAR ²	
	≥2 months	≥0 months	0-1 months	2-11 months	12-59 months	60-119 months	≥120 months	≥2 months	≥0 months
Patients at interval beginning	41,637	42,609	42,609	41,637	37,743	21,116	9,542	41,637	42,609
Person-years (PYs)	265,162	272,156	6,994	32,973	115,343	72,707	44,140	265,162	272,156
C00-06;09-14; 30-32 Upper aerodig. tract	1.36**	1.33**	0.36	1.39	1.39**	1.42*	1.14	2.82**	2.65*
C07-08 Salivary glands	3.77**	3.68**	0.00	6.55**	4.96**	2.02	2.03	1.09**	1.07**
C15 Oesophagus	1.07	1.11	2.89	2.03	1.14	0.96	0.41	0.11	0.18
C16 Stomach	1.08	1.07	0.66	0.88	1.23*	1.04	0.92	1.43	1.26
C18 Colon	1.08	1.07	0.93	1.26*	1.09	1.01	1.04	1.84	1.76
C19-21 Rectosigmoid junction-rectum	0.97	0.96	0.47	0.56*	1.02	1.04	1.03	0.00	-0.40
C22 Liver	1.22*	1.20*	0.57	1.21	1.23*	1.22	1.20	1.77**	1.65*
C23-24 Gallbladder, bile ducts	0.97	0.98	1.22	0.77	0.86	1.31	0.81	-0.07	-0.07
C25 Pancreas	1.04	1.02	0.21	1.02	0.87	1.16	1.22	0.26	0.14
C33-34 Trachea, bronchus, lung	1.24**	1.24**	1.13	1.25**	1.20**	1.33**	1.18**	9.96**	9.81**
C40-41 Bone	0.70	0.68	0.00	1.45	0.00	0.63	1.98	-0.07	-0.07
C43 Skin melanoma	2.38**	2.50**	7.62**	2.16**	2.26**	2.41**	2.72**	4.86**	5.29*
C44 Other skin	1.30**	1.47**	8.70**	1.75**	1.33**	1.18**	1.17**	17.16**	26.56**
C45 Mesothelioma	1.00	0.98	0.00	1.25	0.51	1.58	1.07	0.00	-0.04
C46 Kaposi sarcoma	1.04	1.02	0.00	0.56	1.55	0.46	1.06	0.04	0.00
C47,49 Soft tissues	1.63*	1.63*	1.66	1.40	1.24	1.55	2.74*	0.60*	0.59
C50 Breast	1.13	1.10	0.00	0.70	1.34	1.15	0.87	0.08	0.04
C61 Prostate	1.17**	1.17**	1.03	1.26*	1.15**	1.15*	1.20*	8.18**	8.01**
C62 Testis	0.95	1.06	5.00	0.00	0.62	1.51	1.69	0.00	0.00
C64 Kidney	1.05	1.04	0.61	0.90	1.02	1.23	0.96	0.42	0.33
C65-66;68 Renal pelvis, other urinary	1.01	1.01	0.99	2.07	0.91	0.92	0.75	0.04	0.04
C67 Bladder	1.07	1.05	0.42*	1.09	1.00	1.15	1.09	1.25	0.96
C70-72 Meninges, central nervous system	1.04	1.03	0.56	0.71	1.05	1.31	0.79	0.11	0.07
C73 Thyroid	1.04	1.01	0.00	0.91	1.07	1.04	1.05	0.04	0.04
C81 Hodgkin lymphoma	1.46	1.42	0.00	1.57	1.58	1.06	1.71	0.19	0.15
C82-85;96 Non-Hodgkin lymphomas	1.45**	1.48**	2.51*	1.45	1.49**	1.52**	1.25	3.32**	3.49**
C88-90 Myeloma	1.01	0.99	0.37	1.02	1.04	1.17	0.70	0.04	-0.03
C91-95 Leukemias	1.22*	1.22*	1.01	1.17	1.37*	0.92	1.38	1.32	1.29
C01-96 All sites excl. skin cancers/melanomas	1.17**	1.17**	0.96	1.19**	1.17**	1.20**	1.13**	41.18**	39.94*
C01-96 All sites	1.20**	1.23**	2.41**	1.30**	1.20**	1.19**	1.14**	57.97**	66.10**

(1) Standardized Incidence Ratio

(2) Excess absolute risk (x10,000)

*p<0.05; **p<0.001

Significant values in bold

Table 2. SIR & EAR x 1,000 female skin carcinoma patients by second cancer site and follow-up period

Second cancer site	SIR ¹							EAR ²	
	≥2 months	≥0 months	0-1 months	2-11 months	12-59 months	60-119 months	≥120 months	≥2 months	≥0 months
Patients at interval beginning	33,102	33,774	33,774	33,102	30,368	17,700	8,483	33,102	33,774
Person-years (PYs)	224,045	229,608	5,563	26,406	93,942	62,490	41,207	224,045	229,608
C00-06;09-14; 30-32 Upper aerodig. tract	1.34	1.33	1.15	1.20	1.24	1.56	1.29	0.58	0.57
C07-08 Salivary glands	3.62**	3.54**	0.00	3.45	5.16**	4.03*	0.00	0.63*	0.61*
C15 Oesophagus	1.89*	1.93*	3.79	2.37	2.35*	1.20	1.68	0.45	0.48
C16 Stomach	1.18*	1.17*	0.91	0.92	1.12	1.19	1.44*	1.79	1.74
C18 Colon	1.16*	1.16*	1.01	0.90	1.31**	1.05	1.18	2.50*	2.44*
C19-21 Rectosigmoid junction-rectum	1.09	1.07	0.00	1.62*	0.97	0.99	1.21	0.54	0.39
C22 Liver	1.19	1.17	0.54	0.79	1.31	1.16	1.19	0.67	0.61
C23-24 Gallbladder, bile ducts	0.87	0.86	0.75	0.31	0.90	1.04	0.86	-0.36	-0.35
C25 Pancreas	1.23*	1.21*	0.62	1.60*	1.35*	1.14	0.93	1.52	1.39
C33-34 Trachea, bronchus, lung	1.23*	1.23*	1.09	1.63*	1.16	0.99	1.49*	2.10*	2.05*
C40-41 Bone	1.45	1.42	0.00	0.00	2.12	2.06	0.00	0.09	0.04
C43 Skin melanoma	2.35**	2.40**	4.24*	2.84**	2.10**	2.46**	2.45**	3.04**	3.14**
C44 Other skin	1.02	1.22**	9.96**	1.58**	0.97	0.95	0.94	0.71	6.45**
C45 Mesothelioma	0.76	0.74	0.00	1.40	1.14	0.53	0.00	-0.09	-0.08
C46 Kaposi sarcoma	1.33	1.47	7.60	3.16	0.42	1.75	1.59	0.09	0.13
C47,49 Soft tissues	1.61*	1.65*	3.16	0.00	1.81	2.07	1.47	0.36	0.39
C50 Breast	1.19**	1.18**	0.80	1.19	1.16*	1.15*	1.30*	5.67*	5.40*
C51-52 Vulva, vagina	1.06	1.12	3.89	1.08	0.81	1.07	1.53	0.09	0.17
C53 Cervix uteri	1.03	1.00	0.00	1.29	0.89	0.94	1.31	0.04	0.00
C54 Corpus uteri	0.83	0.85	1.65	1.11	0.67*	1.09	0.62	-0.98	-0.87
C55 Uterus NOS	1.55	1.52	0.00	0.00	1.74	3.01*	0.00	0.18	0.17
C56 Ovary	0.91	0.92	1.42	0.69	0.77	1.00	1.22	-0.36	-0.31
C64 Kidney	1.27*	1.25*	0.58	1.46	1.18	1.25	1.36	0.89	0.83
C65-66;68 Renal pelvis, other urinary	1.94*	1.98*	3.67	2.29	1.22	1.70	3.45*	0.54	0.52
C67 Bladder	1.22	1.22	1.11	1.39	1.38*	0.98	1.13	0.76	0.74
C70-72 Meninges, central nervous system	1.30	1.29	1.00	1.25	1.75*	0.72	1.24	0.58	0.57
C73 Thyroid	1.23	1.22	0.63	2.10*	1.09	1.22	1.04	0.67	0.65
C81 Hodgkin lymphoma	2.02*	1.97*	0.00	0.00	2.37	3.66*	0.00	0.27	0.26
C82-85;96 Non-Hodgkin lymphomas	1.31*	1.33**	1.89	1.66*	1.47*	1.09	1.12	1.61*	1.61*
C88-90 Myeloma	1.17	1.18	1.38	0.72	1.33	0.84	1.58	0.49	0.52
C91-95 Leukemias	1.36*	1.38*	2.08	1.19	1.86*	1.09	0.83	1.34*	1.35*
C01-96 All sites excl. skin cancers/melanomas	1.20**	1.20**	1.06	1.22**	1.22**	1.14**	1.25**	27.72**	27.22**
C01-96 All sites	1.17**	1.20**	2.62**	1.29**	1.18**	1.10**	1.19**	27.99**	33.27**

(1) Standardized Incidence Ratio

(2) Excess absolute risk (x10,000)

*p<0.05; **p<0.001

Significant values in bold

Table 3. SIR by sex, periods and second cancer site (*latency ≥ 2 months*)

Second cancer site	SIR ¹ males			SIR ¹ females		
	1978-1989	1990-1999	2000-2012	1978-1989	1990-1999	2000-2012
Patients at interval beginning	2,065	13,934	37,341	1,332	10,451	33,102
Person-years (PYs)	5,248	54,222	205,693	3,333	41,719	224,045
C00-06;09-14; 30-32 Upper aerodig. tract	1.64	1.63**	1.27**	2.33	2.46*	1.12
C07-08 Salivary glands	19.03*	3.98*	3.43**	0.00	4.15*	3.54**
C15 Oesophagus	0.00	1.16	1.07	0.00	0.48	2.23
C16 Stomach	0.91	1.38**	0.99	0.81	1.06	1.23*
C18 Colon	0.65	1.13	1.07	1.93	1.16	1.15*
C19-21 Rectosigmoid junction-rectum	1.02	1.08	0.94	0.53	1.24	1.07
C22 Liver	0.73	1.22	1.23**	0.00	1.47	1.14
C23-24 Gallbladder, bile ducts	2.00	1.27	0.88	1.15	0.95	0.84
C25 Pancreas	1.43	0.89	1.06	2.05	1.09	1.24
C33-34 Trachea, bronchus, lung	1.65*	1.40**	1.19**	1.13	0.77	1.31**
C40-41 Bone	0.00	0.86	0.67	0.00	3.07	1.09
C43 Skin melanoma	0.00	2.95**	2.31**	0.00	2.23*	2.40**
C44 Other skin	2.24**	1.23**	1.31**	2.66*	0.93	1.03
C45 Mesothelioma	0.00	1.18	0.98	0.00	1.07	0.71
C46 Kaposi sarcoma	0.00	0.96	1.08	0.00	0.89	1.45
C47,49 Soft tissues	0.00	2.18	1.55*	6.41	0.91	1.68
C50 Breast	0.00	1.76	1.00	1.40	1.22*	1.18**
C51-52 Vulva, vagina	-	-	-	0.00	1.28	1.02
C53 Cervix uteri	-	-	-	0.00	0.63	1.20
C54 Corpus uteri	-	-	-	0.00	0.82	0.84
C55 Uterus NOS	-	-	-	0.00	0.68	1.86
C56 Ovary	-	-	-	1.47	0.82	0.92
C61 Prostate	1.40	1.10	1.18**	-	-	-
C62 Testis	0.00	0.00	1.18	-	-	-
C64 Kidney	1.30	0.88	1.09	0.00	1.20	1.29
C65-66;68 Renal pelvis, other urinary	6.61*	1.08	0.93	0.00	2.22	1.91
C67 Bladder	1.07	1.15	1.05	0.92	1.48	1.16
C70-72 Meninges, central nervous system	3.27	1.03	1.00	0.00	1.63	1.25
C73 Thyroid	0.00	0.81	1.07	0.00	1.42	1.22
C81 Hodgkin lymphoma	0.00	0.00	1.78	7.40	0.85	2.16
C82-85;96 Non-Hodgkin lymphomas	0.45	1.63**	1.42**	2.82	1.85**	1.17
C88-90 Myeloma	1.82	1.16	0.95	0.00	1.65	1.08
C91-95 Leukemias	1.88	1.38*	1.16	2.75	1.46	1.32
C01-96 All sites excl. skin cancers/melanomas	1.27*	1.27**	1.15**	1.13	1.21**	1.20**
C01-96 All sites	1.37**	1.26**	1.18**	1.27	1.17**	1.17**

(1) Standardized Incidence Ratio

*p<0.05; **p<0.001

Significant values in bold

Table 4. SIR by sex, age and second cancer site (*latency* ≥ 2 months)

Second cancer site	SIR ¹ males				SIR ¹ females			
	0-44	45-49	60-74	75+	0-44	45-49	60-74	75+
Patients at interval beginning	1,949	7,855	21,481	24,704	2,485	6,685	13,492	21,137
Person-years (PYs)	8,714	35,784	105,12	115,545	10,945	32,149	68,698	112,253
C00-06;09-14; 30-32 Upper aerodig. tract	0.00	1.63*	1.35*	1.33*	4.28	1.92	0.92	1.42
C07-08 Salivary glands	19.15	4.11	4.58**	3.28**	0.00	2.91	2.77	4.09**
C15 Oesophagus	0.00	0.84	1.04	1.11	0.00	0.00	1.25	2.18*
C16 Stomach	0.00	1.41	1.21*	1.02	0.00	1.02	1.44*	1.13
C18 Colon	3.41	1.13	1.11	1.06	0.00	0.89	1.23*	1.16*
C19-21 Rectosigmoid junction-rectum	0.00	1.24	1.00	0.94	0.00	1.43	0.83	1.17
C22 Liver	0.00	1.47	1.32*	1.15	0.00	0.67	0.98	1.26
C23-24 Gallbladder, bile ducts	0.00	0.00	0.90	1.02	0.00	0.00	1.00	0.86
C25 Pancreas	0.00	0.33	0.97	1.10	0.00	1.17	0.96	1.30*
C33-34 Trachea, bronchus, lung	1.67	1.72**	1.28**	1.19**	0.00	0.64	1.28**	1.26**
C40-41 Bone	0.00	0.00	0.48	0.94	0.00	0.00	1.02	1.84
C43 Skin melanoma	6.19**	3.29**	2.67**	1.98**	3.58**	3.93**	2.10**	2.03**
C44 Other skin	1.87	1.72**	1.28**	1.29**	0.87	0.79	0.78*	1.11*
C45 Mesothelioma	0.00	0.91	0.93	1.06	0.00	2.96	0.00	1.03
C46 Kaposi sarcoma	0.00	1.37	1.24	0.96	0.00	0.00	3.58	0.99
C47,49 Soft tissues	0.00	0.82	1.49	1.79*	0.00	2.08	1.40	1.68
C50 Breast	0.00	0.00	1.02	1.27	1.43	1.27*	1.23*	1.13*
C51-52 Vulva, vagina	-	-	-	-	0.00	0.00	1.76	0.92
C53 Cervix uteri	-	-	-	-	0.79	0.67	1.25	1.02
C54 Corpus uteri	-	-	-	-	0.00	0.58	0.79	0.92
C55 Uterus NOS	-	-	-	-	0.00	0.00	0.00	1.82
C56 Ovary	-	-	-	-	1.30	1.14	0.78	0.94
C61 Prostate	0.00	1.68**	1.25**	1.09*	-	-	-	-
C62 Testis	1.13	0.70	0.44	1.43	-	-	-	-
C64 Kidney	1.64	1.71*	0.99	1.03	2.49	1.25	1.47*	1.17
C65-66;68 Renal pelvis, other urinary	0.00	3.27	1.20	0.82	0.00	4.15	1.06	2.16*
C67 Bladder	3.65	1.36	1.12	1.03	0.00	1.84	1.40	1.14
C70-72 Meninges, central nervous system	2.30	1.21	1.17	0.90	0.00	1.53	1.47	1.22
C73 Thyroid	2.16	1.53	1.01	0.75	1.21	1.06	1.31	1.27
C81 Hodgkin lymphoma	0.00	2.37	0.67	2.14	0.00	4.16	1.63	2.04
C82-85;96 Non-Hodgkin lymphomas	4.03*	2.07*	1.49**	1.35**	0.00	1.69	1.17	1.36*
C88-90 Myeloma	0.00	1.13	1.05	0.99	0.00	1.23	1.07	1.21
C91-95 Leukemias	2.29	1.17	1.25	1.20*	0.00	1.70	1.68*	1.26
C01-96 All sites excl. skin cancers/melanomas	2.23**	1.52**	1.23**	1.12**	1.25	1.23**	1.21**	1.20**
C01-96 All sites	2.19**	1.56**	1.24**	1.16**	1.17	1.18**	1.14**	1.18**

(1) Standardized Incidence Ratio

*p<0.05; **p<0.001

significant values in bold

Table 5. SIR by sex, morphological subtypes of first cancer and second cancer site (*latency* ≥ 2 months)

Second cancer site	SIR ¹ males		SIR ¹ females	
	Squamous cell carcinomas	Basal cell carcinomas	Squamous cell carcinomas	Basal cell carcinomas
Patients at interval beginning	8,802	32,247	5,309	27,157
Person-years (PYs)	48,342	213,980	27,791	193,092
C00-06;09-14; 30-32 Upper aerodig. tract	1.78**	1.24*	2.17*	1.22
C07-08 Salivary glands	9.41**	2.30*	7.49**	2.29*
C16 Stomach	1.24*	1.02	3.07*	1.18*
C18 Colon	1.08	1.08	1.11	1.16*
C22 Liver	1.31	1.16*	0.86	1.27*
C25 Pancreas	1.13	1.00	1.46*	1.15
C33-34 Trachea, bronchus, lung	1.47**	1.15**	1.02	1.26*
C43 Skin melanoma	2.12**	2.47**	1.41	2.48**
C44 Other skin	2.46**	0.98	2.55**	0.72**
C47;49 Soft tissues	1.92	1.58*	1.03	1.74*
C50 Breast	0.78	1.23	1.16	1.18**
C54 Corpus uteri	-	-	1.29	0.77*
C61 Prostate	0.93	1.23**	-	-
C65-66;68 Urinary tract	1.25	0.93	3.57*	1.57
C81 Hodgkin lymphoma	1.64	1.44	5.66*	1.55
C82-85;96 Non-Hodgkin lymphomas	1.53*	1.42**	1.78*	1.23*
C91-95 Leukemias	1.59*	1.12	2.28**	1.16
C01-96 All sites excl. skin cancers/melanomas	1.24**	1.15**	1.27**	1.18**
C01-96 All sites	1.48**	1.12**	1.53**	1.10**

(1) Standardized Incidence Ratio

*p<0.05; **p<0.001

significant values in bold